ArticleDrugs - real world outcomes2026
Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Commentary: Pemphigoid associated with quinolone antibiotics: a real-world pharmacovigilance study of the FDA adverse event reporting system and literature-based evidence.Frontiers in immunology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as a first-line therapy for type 2 diabetes in Japan. Precautions of the package inserts for ethical drugs containing DPP-4 inhibitors were revised for pemphigoid between 2016 and 2018. STUDY DESIGN AND
methodsThis is a retrospective study that investigated the number of DPP-4 inhibitor-associated pemphigoid events using the Japanese Adverse Drug Event Report and its estimated annual incidence rate using a nationwide claims database to assess the trend in reported DPP-4 inhibitor-associated pemphigoid events after the release of the revised precautions in Japan.
resultsWe identified 2175 DPP-4 inhibitor-associated pemphigoid events in 2069 case reports. The most common suspected DPP-4 inhibitor was vildagliptin (45.3%), followed by teneligliptin (17.5%), sitagliptin (16.0%), and linagliptin (11.0%). The number of DPP-4 inhibitor-associated pemphigoid events increased from 30 in 2015 to 373 in 2016, reaching a peak of 412 in 2018. Although the estimated annual incidence rate did not exceed 50 per 1,000,000 patients mostly, it exceeded 100 per 1,000,000 for vildagliptin in 2016 and 2018.
conclusionsThe number of reported DPP-4 inhibitor-associated pemphigoid events increased after the revised precautions of package inserts for DPP-4 inhibitors were released.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.